West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System

West (NYSE: WST) completed the sale and transfer of the manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System and associated facilities.

Rhea-AI Summary

West (NYSE: WST) completed the sale and transfer of the manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System and associated facilities. The transaction closed on July 1, 2026. West will continue developing and manufacturing other SmartDose versions, including the SmartDose 10mL On-Body Delivery System.

Positive

• Completion of SmartDose 3.5mL manufacturing and supply rights transfer as planned on July 1, 2026
• Continued development and manufacturing of other SmartDose versions, including SmartDose 10mL On-Body Delivery System

Negative

• Loss of manufacturing and supply rights for SmartDose 3.5mL On-Body Delivery System and associated facilities

Argus Jul 2 session

+0.20% close to close Open Argus

Details

News Market Reaction – WST

On Jul 2, the first trading day after this news, WST closed 0.20% above the previous close.

Data tracked by StockTitan Argus for the Jul 2 session.

Market Context

This announcement reflects portfolio refocusing around SmartDose platforms while retaining larger‑vo...

Analysis

This announcement reflects portfolio refocusing around SmartDose platforms while retaining larger‑volume systems. With shares near a 52‑week high, investors may watch how divested rights affect future growth and capital allocation priorities.

Key Figures

Device volume: 3.5mL Device volume: 10mL

Device volume

3.5mL

SmartDose 3.5mL On-Body Delivery System

Device volume

10mL

SmartDose 10mL On-Body Delivery System

Historical Context

5 past events · Latest: Jun 01

5 events

1. Jun 01

   Leadership change

   24h Move

   -1.3%

   CEO succession with new president and board changes announced.

2. Apr 28

   Investor conferences

   24h Move

   -3.3%

   Participation in upcoming healthcare and growth stock conferences.

3. Apr 23

   Earnings results

   24h Move

   +12.9%

   Strong Q1 sales, EPS growth, buybacks and raised 2026 guidance.

4. Apr 09

   Earnings call notice

   24h Move

   -2.8%

   Announcement of Q1 2026 results release and conference call.

5. Mar 31

   Capacity expansion

   24h Move

   +2.2%

   Dublin facility expansion for high-volume injectable therapies.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

on-body delivery system, injectable drug administration, manufacturing and supply rights, adaptive technology

4 terms

on-body delivery system medical

"SmartDose® 3.5mL On-Body Delivery System and associated facilities."

A wearable device that sticks to a patient’s skin and automatically delivers a medicine over a set time, often replacing repeated injections or daily pills. Investors care because these systems can make treatments easier to use, improve patient adherence, reduce healthcare costs and create product differentiation or recurring revenue streams, all of which affect a drug or device maker’s market potential and regulatory and reimbursement outlook.

injectable drug administration medical

"a global leader in innovative solutions for injectable drug administration, today"

Injectable drug administration is the process of delivering a medicine directly into the body using a needle or infusion — for example into a vein, muscle, or under the skin — instead of swallowing a pill. It matters to investors because injectable products often need specialized manufacturing, packaging, storage and training, face different safety and regulatory hurdles, and can have distinct pricing and distribution dynamics, so they affect a drug’s cost, sales channels and market potential.

manufacturing and supply rights financial

"completed the sale and transfer of the manufacturing and supply rights for"

Manufacturing and supply rights are the legal permissions that allow a company or partner to make and deliver a specific product, often within defined territories, timeframes and quality standards. For investors, these rights determine who controls production, how reliably the product can reach customers, and how much revenue and profit the owner can expect—think of it like hiring someone to bake and ship a popular recipe: who bakes it, where they can sell it, and how consistently they meet demand matters for returns.

adaptive technology technical

"including SmartDose® 10mL On-Body Delivery System, adaptive technology for larger"

Adaptive technology is equipment or software that changes how it works based on user needs or changing conditions, like a thermostat that learns your schedule or a device that adjusts to a patient’s mobility. For investors it matters because adaptability can drive faster adoption, longer product lifecycles and recurring revenue, while also affecting regulatory complexity and competition risk—key factors for valuing growth and durability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the company completed the sale and transfer of the manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities. The transaction closed as planned on July 1, 2026.

West will continue to develop and manufacture all other versions of SmartDose, including SmartDose® 10mL On-Body Delivery System, adaptive technology for larger volumes.

About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites, including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.  

Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. 

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/west-completes-sale-and-transfer-of-the-manufacturing-and-supply-rights-for-smartdose-3-5ml-on-body-delivery-system-302816150.html

SOURCE West Pharmaceutical Services, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did West (NYSE: WST) announce on July 1, 2026 about SmartDose 3.5mL?

West announced it completed the sale and transfer of manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System. According to West, the transaction also includes associated facilities and closed as planned on July 1, 2026.

When did the SmartDose 3.5mL rights transfer close for West (WST)?

The SmartDose 3.5mL rights transfer for West closed on July 1, 2026. According to West, this closing date matched the planned schedule and included both manufacturing and supply rights, as well as associated facilities for the on-body delivery system.

Does West (WST) still develop other SmartDose on-body delivery systems after the 3.5mL sale?

West continues to develop and manufacture other SmartDose on-body delivery systems after the 3.5mL sale. According to West, this includes the SmartDose 10mL On-Body Delivery System and adaptive technology designed for larger-volume injectable drug administration.

How does the SmartDose 3.5mL rights sale affect West's SmartDose 10mL platform?

The sale of SmartDose 3.5mL rights does not include the SmartDose 10mL platform. According to West, the company will continue to develop and manufacture SmartDose 10mL On-Body Delivery System and related adaptive technology for larger-volume injectable drug delivery.

What facilities are included in West's SmartDose 3.5mL rights transfer?

The SmartDose 3.5mL rights transfer includes associated manufacturing and supply facilities. According to West, these facilities are part of the completed transaction for the SmartDose 3.5mL On-Body Delivery System, which closed as planned on July 1, 2026.